Trading Signals: FATE Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Fri. Dec. 22, 2023)(FATE THERAPEUTIC)
| FATE latest price $64.7950 (-1.56%) ($64.7950 - $64.7950) on Tue. Sep. 14, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.61% (three month average) | RSI | 36 | Latest Price | $64.7950(-1.56%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FATE declines -2.4% a day on average for past five trading days. | Weekly Trend | FATE declines -3.4% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support FATE advance at 0% a week (0% probability) IBB(56%) IWO(54%) IBUY(52%) IPO(51%) IWC(51%) | Factors Impacting FATE price | FATE will decline at least -2.305% in a week (0% probabilities). VIXM(-24%) VXX(-10%) UUP(-10%) UNG(-9%) TBT(-4%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.305% (StdDev 4.61%) | Hourly BBV | -1.7 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $53.87(-16.86%) | Resistance Level | $73.16 | 5 Day Moving Average | $67.59(-4.14%) | 10 Day Moving Average | $70.62(-8.25%) | 20 Day Moving Average | $73.16(-11.43%) | To recent high | -32.4% | To recent low | 0% | Market Cap | $5.624b | | | | Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products include immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA. |